Meeting
2022 ASCO Genitourinary Cancers Symposium
ADAM: A multicenter, non-interventional, prospective cohort study for determination of prevalence of homologous recombination repair genes mutations (HRRm) in metastatic castrate resistant prostate cancer (mCRPC)—Interim analysis.
Authors
Boris Alexeev
National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation
Boris Alexeev , Liudmila Lyubchenko , Marat Gordiev , Maxim Filipenko , Yulia Anzhiganova , Alexander Sultanbaev , Alexander Bystrov , Alexander Orlov , Galina Gopp , Evgeny Kopyltsov , Alexander Lykov , Vagif Atduev , Galina Alekseeva , Ovsep Mailyan , Vladislav Semenov , Olga Vedrova , Alexander Perevoschikov , Sergei Andreev , Logacheva Evgenia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 169)
DOI
10.1200/JCO.2022.40.6_suppl.169
Abstract #
169
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2022 ASCO Genitourinary Cancers Symposium
Frequencies of actionable alterations found by somatic tumor sequencing in veterans with metastatic prostate cancer.
First Author: Nicholas George Nickols